{
    "clinical_study": {
        "@rank": "65419", 
        "arm_group": [
            {
                "arm_group_label": "Pyronaridine-artesunate granules (Period 1)", 
                "arm_group_type": "Active Comparator", 
                "description": "In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.\nIn second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
            }, 
            {
                "arm_group_label": "Pyronaridine-artesunate tablets (Period1)", 
                "arm_group_type": "Active Comparator", 
                "description": "In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.\nIn second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the bioavailability of two formulations (tablets and\n      granules for dispersion) of the antimalarial drug Pyramax (which is a combination of\n      pyronaridine and artesunate)."
        }, 
        "brief_title": "Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations, in Healthy Volunteers", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 20 and 45 years, inclusive.\n             (Healthy is defined as no clinically relevant abnormalities identified by a detailed\n             medical history, full physical examination, including blood pressure and pulse rate\n             measurement, 12-lead ECG and clinical laboratory tests)\n\n          -  Weight between 50 kg and 80 kg and Body Mass Index (BMI) calculated using Quetelet's\n             Index - weight(kg)/height (m2) between 18.5 to 27 kg/m2;\n\n          -  An informed consent document signed and dated by the subject (prior to screening and\n             any study activities, including discontinuation of any prohibited medications)\n\n          -  Strictly normal values of alanine aminotransferase(ALT), aspartate aminotransferase\n             (AST), and bilirubin, and normal or abnormal but clinically insignificant results of\n             the other blood and urine laboratory parameters at screening.\n\n          -  Female subjects of non-childbearing potential [i.e., physiologically incapable of\n             becoming pregnant, including any female who was post-menopausal (i.e., one year\n             without menses) or who has undergone sterilization (via hysterectomy or bilateral\n             tubal ligation)]\n\n          -  Female subjects of childbearing potential with a negative urine pregnancy test at\n             screening, and a negative pregnancy blood test on admission, and who :\n\n               -  agree to double barrier method of contraception for 4 weeks before first study\n                  drug administration and throughout the entire study follow up period, or\n\n               -  whose partner has undergone vasectomy and has been negative for sperm for at\n                  least 6 months\n\n          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Known history or evidence of clinically significant disorders such as cardiovascular\n             (including arrhythmia, acute corrected QT interval (QTc) greater or equal to 450\n             milliseconds), respiratory (including active tuberculosis), hepatic, renal,\n             gastrointestinal, immunological (including active HIV-AIDS), neurological (including\n             auditory), endocrine, infectious, malignancy, psychiatric or other abnormality\n             (including head trauma)\n\n          -  Known history of hypersensitivity, allergic or adverse reactions to pyronaridine or\n             artesunate or other artemisinins\n\n          -  Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or\n             Hepatitis C antibody (HCV Ab)\n\n          -  Seropositive HIV antibody, seropositive syphilis [Syphilis reagin test (+)]\n\n          -  Previous exposure to pyronaridine-artesunate (Pyramax)\n\n          -  Present or recent history (last two years) of tobacco abuse (\u226510 cigarettes/day)\n\n          -  Known or suspected alcohol abuse or illicit drug use up to 5 years before the study\n             start or positive findings on urine drug screen\n\n          -  Intake of alcoholic beverages or caffeine-containing food or beverages, such as\n             coffee, tea, chocolate, or cola, 48 hours before study drug administration\n\n          -  Intake of grapefruit, Seville oranges or products containing these from 72 hours\n             before the start of study drug administration\n\n          -  Gilbert's disease\n\n          -  Use of over-the-counter (OTC) medications, including vitamins, analgesics,\n             antipyretics or antacids within 7 days before study drug administration\n\n          -  Use of prescription medications within 14 days before the start of study drug\n             administration or required chronic use of any prescription medication\n\n          -  Use of enzyme-altering agents (e.g. barbiturates, phenothiazines, cimetidine, etc.)\n             within 30 days before the start of study drug administration\n\n          -  Plasma donation within 60 days before the start of study drug administration\n\n          -  Blood donation of 500 mL or more within 60 days before the start of study drug\n             administration\n\n          -  Participation AND having had drug administration in any other clinical study within\n             the 60 days before start of study drug administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868438", 
            "org_study_id": "SP-C-017-12"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pyronaridine-artesunate granules (Period 1)", 
                    "Pyronaridine-artesunate tablets (Period1)"
                ], 
                "intervention_name": "pyronaridine-artesunate granules", 
                "intervention_type": "Drug", 
                "other_name": "Pyramax granules"
            }, 
            {
                "arm_group_label": [
                    "Pyronaridine-artesunate granules (Period 1)", 
                    "Pyronaridine-artesunate tablets (Period1)"
                ], 
                "intervention_name": "Pyronaridine-artesunate tablets", 
                "intervention_type": "Drug", 
                "other_name": "Pyramax tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Artesunate", 
                "Artemisinins", 
                "Pyronaridine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pyronaridine artesunate tablet", 
            "Pyronaridine artesunate granules", 
            "Pyramax tablet", 
            "Pyramax granules", 
            "Bioavailability"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Dept. of Clinical Pharmacology and Therapeutics, Asan Medical Center, Univ. of Ulsan"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area Under the concentration-time Curve from hour 0 to the last sampling point (AUC 0-t) for pyronaridine and dihydroartemisinin (DHA)", 
            "safety_issue": "No", 
            "time_frame": "Pyronaridine PK to Day 43;  DHA PK to 24 hours post dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868438"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medicines for Malaria Venture", 
        "sponsors": {
            "collaborator": {
                "agency": "Shin Poong Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medicines for Malaria Venture", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}